AU2010321047B2 - Humanized antibodies against human IL-22RA - Google Patents

Humanized antibodies against human IL-22RA Download PDF

Info

Publication number
AU2010321047B2
AU2010321047B2 AU2010321047A AU2010321047A AU2010321047B2 AU 2010321047 B2 AU2010321047 B2 AU 2010321047B2 AU 2010321047 A AU2010321047 A AU 2010321047A AU 2010321047 A AU2010321047 A AU 2010321047A AU 2010321047 B2 AU2010321047 B2 AU 2010321047B2
Authority
AU
Australia
Prior art keywords
humanized antibody
human
seq
amino acid
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010321047A
Other languages
English (en)
Other versions
AU2010321047A1 (en
Inventor
Roland Beckmann
Caroline Johnson-Leger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41565648&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010321047(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of AU2010321047A1 publication Critical patent/AU2010321047A1/en
Application granted granted Critical
Publication of AU2010321047B2 publication Critical patent/AU2010321047B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2010321047A 2009-11-19 2010-11-12 Humanized antibodies against human IL-22RA Ceased AU2010321047B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09176525.5 2009-11-19
EP09176525 2009-11-19
US26299809P 2009-11-20 2009-11-20
US61/262,998 2009-11-20
PCT/EP2010/067332 WO2011061119A1 (en) 2009-11-19 2010-11-12 Humanized antibodies against human il-22ra

Publications (2)

Publication Number Publication Date
AU2010321047A1 AU2010321047A1 (en) 2012-05-24
AU2010321047B2 true AU2010321047B2 (en) 2016-06-09

Family

ID=41565648

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010321047A Ceased AU2010321047B2 (en) 2009-11-19 2010-11-12 Humanized antibodies against human IL-22RA

Country Status (20)

Country Link
US (1) US8545844B2 (https=)
EP (1) EP2512511B1 (https=)
JP (1) JP5818804B2 (https=)
KR (1) KR20120098783A (https=)
CN (1) CN102665759B (https=)
AU (1) AU2010321047B2 (https=)
BR (1) BR112012012003A2 (https=)
CA (1) CA2778864C (https=)
EA (1) EA021356B1 (https=)
EC (1) ECSP12011980A (https=)
ES (1) ES2531996T3 (https=)
IL (1) IL219740A0 (https=)
IN (1) IN2012DN03362A (https=)
MX (1) MX2012005791A (https=)
NZ (1) NZ599438A (https=)
PE (1) PE20121560A1 (https=)
PH (1) PH12012500924A1 (https=)
UA (1) UA105405C2 (https=)
WO (1) WO2011061119A1 (https=)
ZA (1) ZA201202793B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4898691B2 (ja) * 2004-10-22 2012-03-21 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法
DK2686347T3 (en) 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
AU2014306867B2 (en) 2013-08-12 2017-10-26 Genentech, Inc. Compositions and method for treating complement-associated conditions
EP3137503A1 (en) * 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
WO2017157325A1 (zh) * 2016-03-18 2017-09-21 舒泰神（北京）生物制药股份有限公司 神经生长因子融合蛋白、制备方法及其用途
GB201612337D0 (en) * 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
EP3630182A4 (en) * 2017-05-24 2021-02-24 Development Center for Biotechnology HUMANIZED ANTIBODIES TO GLOBO H AND THEIR USE IN CANCER TREATMENT
WO2019000105A1 (en) 2017-06-30 2019-01-03 Zymeworks Inc. STABILIZED CHIMERIC FABES
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
CN119836287A (zh) * 2022-06-03 2025-04-15 里奥制药有限公司 Il-22r抗体的液体制剂
EP4704974A1 (en) 2023-03-08 2026-03-11 LEO Pharma A/S Il-22r antibody for use in treating atopic dermatitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047249A1 (en) * 2004-10-22 2006-05-04 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
AU2006226060A1 (en) * 2005-03-25 2006-09-28 Glycart Biotechnology Ag Antigen binding molecules directed to MCSP and having increased Fc receptor binding affinity and effector function
EP1954719A2 (en) * 2005-12-02 2008-08-13 Genentech Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047249A1 (en) * 2004-10-22 2006-05-04 Zymogenetics, Inc. Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Also Published As

Publication number Publication date
CN102665759B (zh) 2015-09-30
US20120230990A1 (en) 2012-09-13
PH12012500924A1 (en) 2012-11-26
JP2013511267A (ja) 2013-04-04
ES2531996T3 (es) 2015-03-23
UA105405C2 (ru) 2014-05-12
JP5818804B2 (ja) 2015-11-18
WO2011061119A1 (en) 2011-05-26
IL219740A0 (en) 2012-07-31
EP2512511A1 (en) 2012-10-24
MX2012005791A (es) 2012-07-03
CA2778864A1 (en) 2011-05-26
KR20120098783A (ko) 2012-09-05
EP2512511B1 (en) 2015-01-07
ECSP12011980A (es) 2012-07-31
AU2010321047A1 (en) 2012-05-24
CA2778864C (en) 2017-06-27
EA021356B1 (ru) 2015-05-29
BR112012012003A2 (pt) 2016-11-29
CN102665759A (zh) 2012-09-12
IN2012DN03362A (https=) 2015-10-23
US8545844B2 (en) 2013-10-01
NZ599438A (en) 2013-12-20
PE20121560A1 (es) 2012-12-05
ZA201202793B (en) 2013-06-26
EA201290360A1 (ru) 2012-11-30

Similar Documents

Publication Publication Date Title
AU2010321047B2 (en) Humanized antibodies against human IL-22RA
JP7410143B2 (ja) 二重特異性抗体及びその用途
JP6526089B2 (ja) 抗神経成長因子抗体ならびにそれを調製および使用する方法
CN103732621B (zh) 抗神经生长因子抗体及其制备和使用方法
KR101637502B1 (ko) 치료용 개 면역글로불린 및 이를 이용하는 방법
KR101584416B1 (ko) 인간 tweak에 대한 항체 및 그의 용도
JP7469292B2 (ja) 抗ｂｔｌａ抗体
US20150232552A1 (en) Antibodies that bind il-23
US20140294815A1 (en) Caninised tumour necrosis factor antibodies and methods of using the same
CN119768425A (zh) 抗-tl1a抗体及其使用方法
KR102571012B1 (ko) 항-il-22r 항체
US20250346644A1 (en) Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
HK1171664A (en) Humanized antibodies against human il-22ra
WO2025185738A1 (zh) 靶向cxcr3的抗原结合蛋白及其应用
JP2025084100A (ja) 抗ｔｎｆｒ２抗体およびその使用の方法
JP2025517490A (ja) 抗ｔｎｆｒ２抗体およびその使用の方法
WO2022262828A1 (zh) 抗il-36r抗体及其用途
NZ621619B2 (en) Caninised tumour necrosis factor antibodies and methods of using the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired